NVS250117P92500
- 0.61
- 0.000.00%
Novartis AG Newsroom
Novartis AG (NOVN) Gets a Sell From Barclays
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Announces Target Price $125
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
Deutsche Bank Sticks to Their Hold Rating for Novartis AG (NOVN)
Kepler Capital Reaffirms Their Buy Rating on Novartis AG (NOVN)
Novartis AG (NOVN) Receives a Hold From Deutsche Bank
HSBC Downgrades Novartis to Reduce, Price Target Is $95
Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation
BMO Capital Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $156
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating
Barclays Remains a Sell on Novartis AG (NOVN)
Novartis AG (NOVN) Gets a Buy From Kepler Capital
Goldman Sachs Sticks to Its Hold Rating for Novartis AG (NOVN)
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
J.P. Morgan Sticks to Their Hold Rating for Novartis AG (NOVN)
UBS Sticks to Their Buy Rating for Novartis AG (NOVN)
Deutsche Bank Sticks to Its Hold Rating for Novartis AG (NOVN)
Novartis Analyst Ratings
Erste Group Downgrades Novartis AG(NVS.US) to Hold Rating